AstraZeneca halts nerve growth drug study
London, December 28, 2010
British drugmaker AstraZeneca has halted studies on Medi-578, which treats nerve growth, to assess data on the product further.
'We saw a reason to put a halt to the studies to evaluate the data and ascertain a sensible path forward,' an AstraZeneca spokeswoman said on Tuesday.
Several leading drug companies around the world have suffered setbacks in plans to develop new products.
Earlier this month, AstraZeneca discontinued development of experimental drug motavizumab and abandoned plans to develop an experimental heart drug known as Certriad along with its American partner Abbott Laboratories.
Earlier this week, Regeneron Pharmaceuticals said US regulators had placed the company's experimental pain drug for osteoarthritis on clinical hold after a patient in another company's trial developed a serious bone disorder.
Regeneron said it and partner Sanofi-Aventis SA were told late last week by the US Food and Drug Administration that the drug, Regn475/SAR164877, was being placed on clinical hold after a patient in another company's trial developed avascular necrosis of a joint.-Reuters